UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM  8-K

 


 

CURRENT REPORT

Pursuant to Section  13 OR 15 (d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): February  16 , 2018

 


 

Nuvectra Corporation

(Exact Name of Issuer as Specified in Charter)

 


 

Delaware

 

001-3752 5

 

30-0513847

(State or Other Jurisdiction of
Incorporation or Organization)

 

(Commission
File Number)

 

(I.R.S. Employer
Identification No.)

 

5830 Granite Parkway, Suite 1100,

Plano, Texas 75024

(Address of Principal Executive Offices)

 

(214) 474-3103

(Registrant ’s Telephone Number, Including Area Code)

 

N/A

(Former name or former address, if changed since last report)

 


Check the appropriate box below if the Form  8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 1 .01       Entry into a Material Definitive Agreement .

 

Second Amendment to Loan and Security Agreement

 

Effective February 16 , 2018 (the “ Effective Date ”), Nuvectra Corporation (the “ Company ”) and its wholly owned subsidiaries, Algostim LLC, Pelvistim LLC and NeuroNexus Technologies, Inc. (together with the Company, “ Nuvectra ”), entered into a Second Amendment (the “ Second Amendment ”) to its Loan and Security Agreement, dated as of March 18, 2016, as amended (the “ Loan Agreement ”), with Oxford Finance LLC and Silicon Valley Bank (collectively, the “ Lenders ”). The Second Amendment revises the Loan Agreement to extend additional credit to Nuvectra, among other revisions.

 

As amended by the Second Amendment, the Loan Agreement provides Nuvectra with a term loan facility in an aggregate principal amount of $45.0 million, comprised of (i) a $27.5 million Term Loan A Commitment, (ii) a $12.5 million Term Loan B Commitment and (iii) a $5.0 million Term Loan C Commitment (the “ Loans ”), in each case provided 50% by each Lender severally and not jointly. The Term Loan A Commitment was funded in full on the Effective Date and used to repay the existing loans outstanding under the Loan Agreement. Nuvectra also drew down the entire Term Loan B Commitment following achievement of $20.0 million in trailing six-month product revenues as of January 31, 2018. Nuvectra may draw on the Term Loan C Commitment beginning on the date Nuvectra achieves trailing six-month product revenues of $25.0 million (the “ Third Tranche Milestone ”) and ending on the earlier of March 31, 2019 or 60 days following the Third Tranche Milestone. The Term Loan C Commitment replaces the revolving line of credit previously available under the Loan Agreement.

 

Under the Second Amendment, the Loans bear interest at a floating rate equal to the prime rate plus 4.15%, subject to a floor of 8.65%. The Second Amendment also extends the amortization period and maturity date of the Loans, with principal payments scheduled to begin on April 1, 2020 and maturity scheduled to occur on September 1, 2022.

 

Until December 31, 2018, Nuvectra is subject to a financial covenant requiring it to achieve quarterly product revenues at levels specified in the Second Amendment. During 2019 and each year that follows, the Second Amendment requires an annual amendment to the Loan Agreement such that Nuvectra will be subject to a financial covenant requiring it to achieve quarterly product revenues equal to the greater of 75% of Nuvectra’s forecasts (subject to Lender approval) and $12.0 million, among other requirements.

 

Nuve ctra paid the Lenders a $788,746 Second Amendment final payment in connection with the Second Amendment. Nuvectra also agreed to pay the Lenders a $1,342,504 termination fee if the Term A Loans become subject to mandatory or voluntary prepayment prior to maturity.

 

2

 

 

Warrants

 

As a condition to the Lenders’ funding under the Second Amendment, the Company issued to Oxford Finance LLC a warrant to purchase 30,245 shares of the Company’s common stock at an exercise price of $9.30 per share, exercisable until February 16, 2028 (the “ Oxford Warrant ”). Under the terms of the warrant previously issued to Silicon Valley Bank on March 18, 2016 (the “ Silicon Valley Warrant ”), Silicon Valley Bank received an automatic adjustment upon the completion of the funding of the Term B Loan Commitment. Upon the funding of the Term Loan B Commitment, the Silicon Valley Warrant automatically adjusted such that (i) the number of shares subject to the Silicon Valley Warrant increased by 30,245 shares, (ii) the exercise price of such increased shares is $9.30 per share and (iii) the Silicon Valley Warrant is exercisable for such shares until February 16, 2028.

 

The above descriptions of the Second Amendment, the Oxford Warrant and the Silicon Valley Warrant are not complete and are qualified by reference to the complete texts of such documents, which are filed as Exhibit 10.1 to this Form 8-K, Exhibit 4.1 to this Form 8-K and Exhibit 4.2 to the Company’s Form 8-K filed on March 18, 2016, respectively, and incorporated by reference into this Item 1.01.

 

Item 2.03      Creation of Financial Obligation .

 

The information regarding the Second Amendment included in Item 1.01 is incorporated by reference into this Item 2.03.

 

Item 3.02       Unregistered Sales of Equity Securities .

 

The information regarding the Oxford Warrant and the Silicon Valley Warrant included in Item 1.01 is incorporated by reference into this Item 3.02. The Company relied on exemptions from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D, Rule 506 thereunder, to issue the Oxford Warrant and the Silicon Valley Warrant.

 

Item  9.01       Financial Statements and Exhibits.

 

Exhibit
No.

 

Document

     

4.1

 

Warrant to Purchase Common Stock, dated February 16, 2018, issued to Oxford Finance LLC.

10.1

 

Second Amendment to Loan and Security Agreement, dated February 16, 2018, among Nuvectra Corporation, Algostim LLC, Pelvistim LLC, NeuroNexus Technologies, Inc. and Oxford Finance LLC and Silicon Valley Bank.

99.1

 

Press Release dated  February 20, 2018.

    

3

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 21, 2018

 

 

 

 

NUVECTRA CORPORATION

 

 

 

 

By:

/s/ Walter Z. Berger

 

 

Name: Walter Z. Berger

 

 

Title: Chief Operating Officer and Chief Financial Officer

 

4

 

 

EXHIBIT  INDEX

 

Exhibit
No.

 

Document

     

4.1

 

Warrant to Purchase Common Stock, dated February 16, 2018, issued to Oxford Finance LLC.

10.1

 

Second Amendment to Loan and Security Agreement, dated February 16, 2018, among Nuvectra Corporation, Algostim LLC, Pelvistim LLC, NeuroNexus Technologies, Inc. and Oxford Finance LLC and Silicon Valley Bank.

99.1

 

Press Release dated February 20, 2018.

 

5

Exhibit 4.1

 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ ACT ”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

WARRANT TO PUR CHASE STOCK

 

Company :

NUVECTRA CORPORATION, a Delaware corporation

Number of Shares :

30,245

Type/Series of Stock :

Common Stock (“ Common Stock ”)

Warrant Price :

$ 9.299

Issue Date :

February 16, 2018

Expiration Date :

February 16, 2028     See also Section 5.1(b).

Credit Facility :

This Warrant to Purchase Stock (“ Warrant ”) is issued in connection with that certain Loan and Security Agreement of even date herewith among Oxford Finance LLC, as Lender and Collateral Agent, the Lenders from time to time party thereto, including Silicon Valley Bank, and the Company (as modified, amended and/or restated from time to time, the “ Loan Agreement ”).

 

THIS WARRANT CERTIFIES THAT, for good and valuable consideration, OXFORD FINANCE LLC (“ Oxford ” and, together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “ Holder ”) is entitled to purchase the number of fully paid and non-assessable shares (the “ Shares ”) of the Common Stock of the above-named company (the “ Company ”) at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant.

 

SECTION 1.      EXERCISE.

 

1.1      Method of Exercise . Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.

 

 

 

 

1.2      Cashless Exercise . On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula:

 

X = Y(A-B)/A

 

where:

 

 

X =

the number of Shares to be issued to the Holder;

 

 

Y =

the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);

 

 

A =

the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and

 

 

B =

the Warrant Price.

 

1.3      Fair Market Value . If the Company’s Common Stock is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “ Trading Market ”), the Fair Market Value of a Share shall be the closing price or last sale price of a share of Common Stock reported for the trading day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Company’s Common Stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the Fair Market Value of a Share in its reasonable good faith judgment.

 

1.4      Delivery of Certificate and New Warrant . Within a reasonable time after Holder exercises this Warrant in the manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Shares not so acquired.

 

1.5      Replacement of Warrant . On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount.

 

1.6      Treatment of Warrant Upon Acquisition of Company .

 

(a)      Acquisition . For the purpose of this Warrant, “ Acquisition ” means any transaction or series of related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in each case, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders beneficially own a majority of the outstanding voting power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power to a person or entity or to a group of persons or entities acting together.

 

2

 

 

(b)      Treatment of Warrant at Acquisition . In the event of an Acquisition in which the consideration to be received by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “ Cash/Public Acquisition ”), either (i) Holder shall exercise this Warrant pursuant to Section 1.1 and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation of such Acquisition or (ii) if Holder elects not to exercise the Warrant, this Warrant will expire immediately prior to the consummation of such Acquisition.

 

(c)     The Company shall provide Holder with written notice of its request relating to the Cash/Public Acquisition (together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash/Public Acquisition giving rise to such notice), which is to be delivered to Holder not less than seven (7) Business Days prior to the closing of the proposed Cash/Public Acquisition . In the event the Company does not provide such notice, then if, immediately prior to the Cash/Public Acquisition, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall promptly notify the Holder of the number of Shares (or such other securities) issued upon such exercise to the Holder and Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as the date thereof.

 

(d)     Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant.

 

(e)     As used in this Warrant, “ Marketable Securities ” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition if Holder were to exercise this Warrant on or prior to the closing thereof is then traded in any Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition.

 

3

 

 

SECTION 2.      ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

 

2.1      Stock Dividends, Splits, Etc . If the Company declares or pays a dividend or distribution on the outstanding shares of the Common Stock payable in securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Common Stock by reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Common Stock are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.

 

2.2      Reclassification, Exchange, Combinations or Substitution . Upon any event whereby all of the outstanding shares of the Common Stock are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events.

 

2.3      Intentionally Omitted .

 

2.4      Intentionally Omitted .

 

2.5      No Fractional Share . No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price.

 

2.6      Notice/Certificate as to Adjustments . Upon each adjustment of the Warrant Price, class and/or number of Shares, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, class and number of Shares in effect upon the date of such adjustment.

 

4

 

 

SECTION 3.      REPRESENTATION S AND COVENANTS OF THE COMPANY.

 

3.1      Representations and Warranties . The Company represents and warrants to, and agrees with, the Holder as follows:

 

(a)     The initial Warrant Price referenced on the first page of this Warrant is not greater than the lesser of (i) the average of the closing price of a share of Common Stock reported on the Trading Market for the 10 consecutive trading days (or such lesser number of consecutive trading days that the Company ’s Common Stock has been traded on a Trading Market) ending immediately prior to the funding date of the Term A Loans (as defined in the Loan Agreement and used herein, the “ Term A Loans ”) and (ii) the closing price of a share of Common Stock reported on the Trading Market for the trading day ending immediately prior to the funding date of the Term A Loans.

 

(b)     All Shares which may be issued upon the exercise of this Warrant shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws . The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of securities as will be sufficient to permit the exercise in full of this Warrant.

 

3.2      Notice of Certain Events . If the Company proposes at any time to:

 

(a)     declare any dividend or distribution upon the outstanding shares of the Company ’s stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend;

 

(b)     offer for subscription or sale pro rata to the holders of the outstanding shares of the Company ’s stock any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);

 

(c)     effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the Common Stock; or

 

(d)     effect an Acquisition or to liquidate, dissolve or wind up;

 

then, in connection with each such event, the Company shall give Holder:

 

(1)     at least seven (7) Business Days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Common Stock will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above; and

 

5

 

 

(2)     in the case of the matters referred to in (c) and (d) above at least seven (7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the class will be entitled to exchange their shares for the securities or other property deliverable upon the occurrence of such event).

 

Reference is made to Section 1.6(c) whereby this Warrant will be deemed to be exercised pursuant to Section 1.2 hereof if the Company does not give written notice to Holder of a Cash/Public Acquisition as required by the terms hereof . Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements.

 

SECTION 4.      REPRESENTATIONS, WARRANTIES OF THE HOLDER.

 

The Holder represents and warrants to the Company as follows:

 

4.1      Purchase for Own Account . This Warrant and the securities to be acquired upon exercise of this Warrant by Holder are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant or the Shares.

 

4.2      Disclosure of Information . Holder is aware of the Company’s business affairs and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.

 

4.3      Investment Experience . Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons.

 

4.4      Accredited Investor Status . Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.

 

4.5      The Act . Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act.

 

6

 

 

4.6      No Voting Rights . Except as set forth herein, Holder, as a Holder of this Warrant, will not have any voting or other rights of a stockholder of the Company until the exercise of this Warrant.

 

SECTION 5.      MISCELLANEOUS.

 

5.1      Term; Automatic Cashless Exercise Upon Expiration .

 

(a)      Term . Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from time to time on or before 6:00 PM, Eastern time, on the Expiration Date and shall be void thereafter.

 

(b)      Automatic Cashless Exercise upon Expiration . In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder.

 

5.2      Legends . Each certificate evidencing Shares (and each certificate evidencing the securities issued upon conversion of any Shares, if any) shall be imprinted with a legend in substantially the following form:

 

THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ ACT ”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO OXFORD FINANCE LLC DATED February 16, 2018 , MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

5.3      Compliance with Securities Laws on Transfer . This Warrant and the Shares issued upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to an affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act.

 

7

 

 

5.4      Transfer Procedure . After receipt by Oxford of the executed Warrant, Oxford may transfer all or part of this Warrant to one or more of Oxford’s affiliates (each, an “ Oxford Affiliate ”), by execution of an Assignment substantially in the form of Appendix 2. Subject to the provisions of Article 5.3 and upon providing the Company with written notice, Oxford, any such Oxford Affiliate and any subsequent Holder, may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if any) to any other transferee, provided, however, in connection with any such transfer, the Oxford Affiliate(s) or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable).

 

5.5      Notices . All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise:

 

Oxford Finance
LLC 133 N. Fairfax Street
Alexandria, VA 22314
Attn: Legal Department
Telephone: (703) 519-4900
Facsimile: (703) 519-5225
Email: LegalDepartment@oxfordfinance.com

 

8

 

 

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address:

 

Nuvectra Corporation
5830 Granite Parkway, Suite 1100
Plano, TX 75024
Attn: Melissa G. Beare
Telephone: (973) 668-4107
Facsimile: (469) 362-8441
Email: mbeare@nuvectramed.com

 

5.6      Waiver . This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought.

 

5.7      Attorneys ’ Fees . In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees.

 

5.8      Counterparts; Facsimile/Electronic Signatures . This Warrant may be executed in counterparts, all of which together shall constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.

 

5.9      Governing Law . This Warrant shall be governed by and construed in accordance with the laws of the State of California, without giving effect to its principles regarding conflicts of law.

 

5.10      Headings . The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant.

 

5.11      Business Days . “ Business Day ” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed.

 

[Remainder of page left blank intentionally]

 

[Signature page follows]

 

9

 

 

IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives effective as of the Issue Date written above.

 

“COMPANY”

 

NUVECTRA CORPORATION

 

 

By:   /s/ Walter Z. Berger

 

Name: Walter Z. Berger

(Print)

 

Title: Chief Operating Officer and Chief Financial Officer

 

 

 

“HOLDER”

 

OXFORD FINANCE LLC

 

 

By: /s/ Colette H. Featherly

 

Name: Colette H. Featherly

(Print)

 

Title: Senior Vice President

 

 

 

 

 

 

[Signature Page to Warrant to Purchase Stock]

 

 

 

APPENDIX 1

 

NOTICE OF EXERCISE

 

1.     The undersigned Holder hereby exercises its right to purchase _______ shares of the Common Stock of NUVECTRA CORPORATION (the “Company”) in accordance with the attached Warrant To Purchase Stock, and tenders payment of the aggregate Warrant Price for such shares as follows:

 

[  ]

Check in the amount of $_______ payable to the order of the Company enclosed herewith

   

[  ]

Wire transfer of immediately available funds to the Company ’s account

   

[  ]

Cashless Exercise pursuant to Section 1.2 of the Warrant

   

[  ]

Other [Describe]                                                                                 

 

2.       Please issue a certificate or certificates representing the Shares in the name specified below:

 

                                                                              

Holder ’s Name

 

                                                                              

 

                                                                              

(Address)

 

3.       By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section 4 of the Warrant to Purchase Stock as of the date hereof.

 

 

HOLDER:

 

                                                                                

 

By:                                                                            

 

Name:                                                                       

 

Title:                                                                         

 

Date:                                                                         

 

 

Appendix 1

 

 

 

APPENDIX 2

 

ASSIGNMENT

 

For value received, Oxford Finance LLC hereby sells, assigns and transfers unto

 

Name:           [OXFORD TRANSFEREE]

 

Address:                                                                       

 

Tax ID:                                                                         

 

that certain Warrant to Purchase Stock issued by NUVECTRA CORPORATION (the “ Company ”), on February 16, 2018 (the “ Warrant ”) together with all rights, title and interest therein.

 

 

OXFORD FINANCE LLC

 

 

By:                                                                           

 

Name:                                                                       

 

Title:                                                                          

Date:                                                                         

 

 

By its execution below, and for the benefit of the Company, [OXFORD TRANSFEREE] makes each of the representations and warranties set forth in Article 4 of the Warrant and agrees to all other provisions of the Warrant as of the date hereof.

 

 

[OXFORD TRANSFEREE]

 

By:                                                                         

 

Name:                                                                         

 

Title:                                                                         

 

 

Appendix 2

Exhibit 10.1

 

SECOND AMENDMENT TO
LOAN AND SECURITY AGREEMENT

 

THIS SECOND AMENDMENT to Loan and Security Agreement (this “ Amendment ”) is entered into as of February 16, 2018, by and between OXFORD FINANCE LLC , a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“ Oxford ”), as collateral agent (in such capacity, “ Collateral Agent ”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time (each a “ Lender ” and collectively, the “ Lenders ”) including Oxford in its capacity as a Lender and SILICON VALLEY BANK , a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“ Bank ” or “ SVB ”) and NUVECTRA CORPORATION , a Delaware corporation (“ Nuvectra ”), ALGOSTIM, LLC , a Delaware limited liability company (“ Algostim ”), PELVISTIM LLC , a Delaware limited liability company (“ PelviStim ”), and NEURONEXUS TECHNOLOGIES, INC. , a Michigan corporation (“ NeuroNexus ”), each with offices located at 5830 Granite Parkway, Suite 1100, Plano, TX 75024 (Nuvectra, Algostim, PelviStim and NeuroNexus are individually and collectively, jointly and severally, “ Borrower ”).

Recitals

 

A.      Collateral Agent, Lenders and Borroywer have entered into that certain Loan and Security Agreement dated as of March 18, 2016 (as amended from time to time, including by that certain First Amendment to Loan and Security Agreement dated as February 14, 2017, the “ Loan Agreement ”).

 

B.      Lender s have extended credit to Borrower for the purposes permitted in the Loan Agreement.

 

C.      Borrower has requested that Collateral Agent and Lenders (i) extend additional credit to Borrower, (ii) remove the Revolving Line (as in effect prior to the Second Amendment Effective Date), and (iii) make certain other revisions to the Loan Agreement as more fully set forth herein.

 

D.      Collateral Agent and Lenders have agreed to modify such consent and to amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.

 

Agreement

 

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:

 

 

1.         Definitions. Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.

 

2.        Amen dment s to Loan Agreement .

 

2.1     Sec tion 2. 2 (Term Loans ) . Section 2.2 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

2.2      Term Loans .

 

(a)      Availability .

 

(i)     Subject to the terms and conditions of this Agreement, prior to the Second Amendment Effective Date, the Lenders, severally and not jointly, made loans to Borrower according to (X) each Lender’s Term Loan Commitment as set forth on Schedule  1.1 hereto (as in effect prior to the Second Amendment Effective Date) (such term loans are hereinafter referred to collectively as the “ Original Term Loans ”) and (Y) each Lender’s Revolving Line Commitment as set forth on Schedule  1.1 hereto (as in effect prior to the Second Amendment Effective Date) (such revolving loans are hereinafter referred to collectively as the “ Original Revolving Loans ” and, together with the Original Term Loans, collectively, the “ Original Loans ”).

 

1

 

 

(ii)     Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, to make term loans to Borrower on the Second Amendment Effective Date as follows:

 

1)     SVB shall make a term loan to Borrower in an amount equal to Thirteen Million Seven Hundred Fifty Thousand Dollars ($13,750,000.00) to refinance the Original Term Loans by SVB (the “ SVB Term A Loan ”).

 

2)     Oxford shall make a term loan to Borrower in an amount equal to Thirteen Million Seven Hundred Fifty Thousand Dollars ($13,750,000.00) to refinance the Original Term Loans by Oxford (the “ Oxford Term A Loan ”, and together with the SVB Term A Loan, each, a “ Term A Loan ” and collectively, the “ Term A Loans ”). After repayment, no Term A Loan may be re-borrowed.

 

(iii)     Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Second Draw Period, to make term loans to Borrower in an aggregate amount equal to Twelve Million Five Hundred Thousand Dollars ($12,500,000.00) and disbursed in a single advance according to each Lender ’s Term B Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to singly as a “ Term B Loan ”, and collectively as the “ Term B Loans ”). After repayment, no Term B Loan may be re-borrowed.

 

(iv)     Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Third Draw Period, to make term loans to Borrower in an aggregate amount equal to Five Million Dollars ($5,000,000.00) and disbursed in a single advance according to each Lender ’s Term C Loan Commitment as set forth on Schedule 1.1 hereto (such term loans are hereinafter referred to singly as a “ Term C Loan ”, and collectively as the “ Term C Loans ”; each Term A Loan, Term B Loan or Term C Loan is hereinafter referred to singly as a “ Term Loan ” and the Term A Loans, Term B Loans and Term C Loans are hereinafter referred to collectively as the “ Term Loans ”). After repayment, no Term C Loan may be re-borrowed.

 

(b)      Repayment . Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender’s Term Loan, (2) the effective rate of interest, as determined in Section 2.4(a), and (3) a repayment schedule (i) with respect to the Term A Loans, equal to (A) thirty (30) months, if the Term B Loans are funded prior to the end of the Second Draw Period, or (B) thirty-six (36) months, if the Term B Loans are not funded prior to the end of the Second Draw Period, (ii) with respect to the Term B Loans, equal to thirty (30) months, and (iii) with respect to the Term C Loans, equal to (A) thirty (30) months, if the Term B Loans are funded prior to the end of the Second Draw Period, or (B) if the Term B Loans are not funded prior to the end of the Second Draw Period, the number of months remaining during the period commencing on the second (2nd) Payment Date following the Funding Date of the Term C Loans and ending on the Maturity Date. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).

 

2

 

 

(c)      Mandatory Prepayments . If the Term Loans are accelerated following the occurrence of an Event of Default, Borrower shall immediately pay to Lenders, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (ii) the Final Payment, (iii) the Prepayment Fee, plus (iv) all other Obligations that are due and payable, including Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts. Notwithstanding (but without duplication with) the foregoing, on the Maturity Date, if the Final Payment had not previously been paid in full in connection with the prepayment of the Term Loans in full, Borrower shall pay to Collateral Agent, for payment to each Lender in accordance with its respective Pro Rata Share, the Final Payment in respect of the Term Loans.

 

(d)      Permitted Prepayment of Term Loans . Borrower shall have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least thirty (30) days prior to such prepayment, and (ii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (B) the Final Payment, (C) the Prepayment Fee, plus (D) all other Obligations that are due and payable, including Lenders’ Expenses and interest at the Default Rate with respect to any past due amounts.”

 

2.2      Section 2.3 (Revolving Advances) . Section 2.3 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

2.3       Intentionally Omitted .”

 

2.3      Section 2.5 (Secured Promissory Notes) . Section 2.5 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

2.5     Secured Promissory Notes. The Term Loans shall be evidenced by a Secured Promissory Note or Notes in the form attached as Exhibit D hereto (other than the two Original Term Loans made by Oxford and that are being refinanced on the Second Amendment Effective Date, which shall be evidenced by Amended and Restated Secured Promissory Notes in the form attached as Exhibit E hereto) (each a “ Secured Promissory Note ”), and shall be repayable as set forth in this Agreement. Borrower irrevocably authorizes each Lender to make or cause to be made, on or about the Funding Date of any Term Loan or at the time of receipt of any payment of principal on such Lender’s Secured Promissory Note, an appropriate notation on such Lender’s Secured Promissory Note Record reflecting the making of such Term Loan or (as the case may be) the receipt of such payment. The outstanding amount of each Term Loan set forth on such Lender’s Secured Promissory Note Record shall be prima facie evidence of the principal amount thereof owing and unpaid to such Lender, but the failure to record, or any error in so recording, any such amount on such Lender’s Secured Promissory Note Record shall not limit or otherwise affect the obligations of Borrower under any Secured Promissory Note or any other Loan Document to make payments of principal of or interest on any Secured Promissory Note when due. Upon receipt of an affidavit of an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note , Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor.”

 

2.4     Section 2.6 (Fees – Final Payment ) . Section 2.6(c) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

“(c )      Final Payment .

 

3

 

 

(i)     The Final Payment, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares; and

 

(ii)     A fully-earned, non-refundable final payment, due on the Second Amendment Effective Date in connection with the Original Term Loans, in the aggregate amount of Seven Hundred Eighty-Eight Thousand Seven Hundred Forty-Five and 56/100 Dollars ($788,745.56) (the “ Second Amendment Final Payment ”), payable to Oxford, in its capacity as a Lender, and SVB, to be shared in accordance with their respective Pro Rata Shares. For the sake of clarity, the Second Amendment Final Payment shall not reduce the Final Payment otherwise due in connection with Section 2.6(c)(i) hereof.”

 

2.5     Section 2.6 (Fees – Prepayment Fee) . Section 2.6(d) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

“(d)       Prepayment Fee . The Prepayment Fee, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares. For the sake of clarity, the Funding Date of each Term A Loan is the Second Amendment Effective Date.”

 

2.6     Section 2.6 (Fees Termination Fee ) . A new Section 2.6(i) of the Loan Agreement hereby is added to read as follows:

 

“(d)       Termination Fee . A termination fee in the amount of One Million Three Hundred Forty-Two Thousand Five Hundred Four and 44/100 Dollars ($1,342,504.44) (the “ Termination Fee ”), to be shared between the Lenders in accordance with their respective Pro Rata Shares, which Termination Fee shall be due and payable if the Term A Loans are subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise.”

 

2.7     Section 3.2 ( Conditions Precedent to all Credit Extensions ) . Section 3.2 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

3.2     Conditions Precedent to all Credit Extensions . The obligation of each Lender to make each Credit Extension, including the initial Credit Extension, is subject to the following conditions precedent:

 

(a)      receipt by (i) the Lenders of an executed Disbursement Letter in the form of Exhibit B-1 attached hereto; and (ii) SVB of an executed Loan Payment/Advance Request Form in the form of Exhibit B-2 attached hereto;

 

(b)      the representations and warranties in Section 5 hereof shall be true, accurate and complete in all material respects on the date of the Disbursement Letter (and the Loan Payment/Advance Request Form) and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, and no Event of Default shall have occurred and be continuing or result from the Credit Extension. Each Credit Extension is Borrower’s representation and warranty on that date that the representations and warranties in Section 5 hereof are true, accurate and complete in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date;

 

(c)      in such Lender’s sole discretion, there has not been any Material Adverse Change;

 

4

 

 

(d)      to the extent not delivered at the Effective Date, duly executed original Secured Promissory Notes and Warrants, in number, form and content acceptable to each Lender, and in favor of each Lender according to its Term Loan Commitment Percentage, with respect to each Credit Extension made by such Lender after the Effective Date, and, provided that the Warrants for any Credit Extension made by a Lender after the Second Amendment Effective Date shall grant to such Lender the right to acquire shares of common stock of Borrower in an amount equal to (1) four and one-half percent (4.50%) of the amount of such Credit Extension, divided by (2) the lower of (i) the average closing price of such common stock for the previous ten days of trading (calculated on the day prior to the Funding Date for such Credit Extension) and (ii) the closing price of such common stock on the trading day prior to the Funding Date for such Credit Extension, and such Warrants shall have an exercise price equal to such price determined pursuant to the foregoing clause (2); and

 

(e)      payment of the fees and Lenders’ Expenses then due as specified in Section 2.6 hereof.”

 

2.8     Section 3.4 ( P rocedures for Borrowing ) . Section 3.4(b) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

(b)       Intentionally Omitted .”

 

2.9     Section 5.9 (Use of Proceeds) . Section 5.9 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

5.9     Use of Proceeds . Borrower shall use the proceeds of the Credit Extensions solely as working capital and to fund its general business requirements, and to refinance the Original Loans, in accordance with the provisions of this Agreement, and not for personal, family, household or agricultural purposes.”

 

2.10     Section 5.11 (Accounts Receivable) . Section 5.11 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

5 .11     Intentionally Omitted .”

 

2.11     Section 6.2 (Financial Statements, Reports, Certificates) . Section 6.2(a)(iii) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

(iii)       as soon as available after approval thereof by Borrower’s Board of Directors, but no later than the earlier of thirty (30) days after the last day of each of Borrower’s fiscal years or within seven (7) Business Days of approval by Borrower’s Board of Directors, Borrower’s annual financial projections for the entire current fiscal year as approved by Borrower’s Board of Directors, which such annual financial projections shall be set forth in a quarter-by-quarter format (such annual financial projections as originally delivered to Collateral Agent and the Lenders are referred to herein as the “ Annual Projections ”; provided that, any revisions of the Annual Projections approved by Borrower’s Board of Directors shall be delivered to Collateral Agent and the Lenders no later than seven (7) Business Days after such approval);”.

 

2.12     Section 6.2 (Financial Statements, Reports, Certificates) . Section 6.2(a)(ix) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

(ix)      Intentionally Omitted .”

 

2.13     Section 6.10 (Financial Covenant) . Section 6.10 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

5

 

 

6.10     Financial Covenant . Borrower shall achieve product revenue (determined in accordance with GAAP), measured as of the last day of each fiscal quarter on a trailing three (3) month basis, greater than or equal to the amounts set forth below for the corresponding measuring periods.

 

Measuring Period End Date

 

Minimum Product Revenue

December 31, 2017

 

$7,200,000

March 31, 2018

 

$8,075,000

June 30, 2018

 

$8,500,000

September 30, 2018

 

$9,860,000

December 31, 2018

 

$12,070,000

 

 

F or the 2019 fiscal year and each year thereafter, new minimum product revenue levels shall be set by the mutual agreement of Borrower, Collateral Agent and the Lenders based on the Annual Projections delivered by Borrower to each Lender pursuant to Section 6.2(a)(iii) hereof (without regard, however, to any revisions to such Annual Projections provided by Borrower pursuant to Section 6.2(a)(iii)) and pursuant to an amendment to this Agreement which Borrower hereby agrees to execute by no later than February 28 th of each year. Such revenue projections shall be acceptable to Collateral Agent and Lenders in their sole discretion and in any case shall require Borrower achieve product revenue (determined in accordance with GAAP), measured as of the last day of each fiscal quarter on a trailing three (3) month basis, greater than or equal to the greater of (i) seventy-five percent (75%) of the product revenue target as set forth in such, and (ii) Twelve Million Dollars ($12,000,000.00). Furthermore, such projections shall demonstrate year over year revenue growth (determined by comparing each individual quarter with the corresponding quarter from the previous year) and it shall be an immediate Event of Default if Borrower, Collateral Agent and Lenders fail to enter into the aforementioned amendment on or prior to February 28 of each year.”

 

2.14     Section 6.14 (Accounts Receivable) . Section 6.14 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

6.14     Intentionally Omitted .”

 

2.15     Section 8.1 (Payment Default) . Section 8.1 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

8.1     Payment Default . Borrower fails to (a) make any payment of principal or interest on any Credit Extension on its due date, or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or the date of acceleration pursuant to Section 9.1 (a) hereof). During the cure period, the failure to cure the payment default is not an Event of Default (but no Credit Extension will be made during the cure period);”

 

2.16     Section 9.4 ( Application of Payments and Proceeds ) . Section 9.4 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

6

 

 

9.4     Application of Payments and Proceeds . Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during the continuance of an Event of Default, (a) Borrower irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Collateral Agent from or on behalf of Borrower or any of its Subsidiaries of all or any part of the Obligations, and, as between Borrower on the one hand and Collateral Agent and Lenders on the other, Collateral Agent shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Collateral Agent may deem advisable notwithstanding any previous application by Collateral Agent, and (b) the proceeds of any sale of, or other realization upon all or any part of the Collateral shall be applied: first, to the Lenders’ Expenses; second, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code, would have accrued on such amounts); third, to the principal amount of the Obligations outstanding; and fourth, to any other indebtedness or obligations of Borrower owing to Collateral Agent or any Lender under the Loan Documents. Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct. In carrying out the foregoing, (x) amounts received shall be applied in the numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category. Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation “ratably,” “proportionally” or in similar terms shall refer to Pro Rata Share unless expressly provided otherwise. Collateral Agent, or if applicable, each Lender, shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender’s portion of any Term Loan and the ratable distribution of interest, fees and reimbursements paid or made by Borrower. Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date; provided, however, if it is later determined that a Lender received more than its ratable share of scheduled payments made on any date or dates, then such Lender shall remit to Collateral Agent or other Lenders such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Collateral Agent. If any payment or distribution of any kind or character, whether in cash, properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution in excess of such Lender’s ratable share shall be received by such Lender in trust for and shall be promptly paid over to the other Lender for application to the payments of amounts due on the other Lenders’ claims. To the extent any payment for the account of Borrower is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to ensure that such return of payment is on a pro rata basis. If any Lender shall obtain possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for Collateral Agent and other Lenders for purposes of perfecting Collateral Agent’s security interest therein.”

 

2.17     Section 10 ( Notices ) . The reference to VLP Law Group LLP and such Person’s address in Section 10 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

DLA Piper LLP (US)

500 8 th Street, NW

Washington, DC 20004

Attn: Eric Eisenberg

Fax: (202) 799-5211

E-mail: eric.eisenberg@dlapiper.com”

 

The reference to Norton Rose Fulbright and such Person ’s address in Section 10 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

“Dorsey & Whitney LLP

300 Crescent Court, Suite 400

Dallas, TX 75201

Attn: Laura Kalesnik

Fax: (214) 981-9901

E-mail: kalesnik.laura@dorsey.com”

 

 

7

 

 

2.18     Section 12.6 (Amendments in Writing; Integration) . Section 12.6(a)(i) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

“(i)      no such amendment, waiver or other modification that would have the effect of increasing or reducing a Lender’s Term Loan Commitment, Term Loan Commitment Percentage shall be effective as to such Lender without such Lender’s written consent;”

 

2.19     Section 12.6 ( Amendments in Writing; Integration ) . Section 12.6(a)(iii) of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

“(iii)      no such amendment, waiver or other modification shall, unless signed by all the Lenders directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Term Loan (B) postpone the date fixed for, or waive, any payment of principal of any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder (other than late charges or for any termination of any commitment); (C) change the definition of the term “Required Lenders” or the percentage of Lenders which shall be required for the Lenders to take any action hereunder; (D) release all or substantially all of any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any Guarantor of all or any portion of the Obligations or its guaranty obligations with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder); (E) amend, waive or otherwise modify this Section 12.6 or the definitions of the terms used in this Section 12.6 insofar as the definitions affect the substance of this Section 12.6; (F) consent to the assignment, delegation or other transfer by Borrower of any of its rights and obligations under any Loan Document or release Borrower of its payment obligations under any Loan Document, except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement; (G) amend any of the provisions of Section 9.4 or amend any of the definitions of Pro Rata Share, Term Loan Commitment, Term Loan Commitment Percentage, or that provide for the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder; (H) subordinate the Liens granted in favor of Collateral Agent securing the Obligations; or (I) amend any of the provisions of Section 12.10. It is hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the preceding clauses (C), (D), (E), (F), (G) and (H) of the preceding sentence;”

 

2.20      Section 12. 1 2 ( Cooperation of Borrower ) . Section 12.2 of the Loan Agreement hereby is amended and restated in its entirety to read as follows:

 

12.12   Cooperation of Borrower . If necessary, Borrower agrees to (i) execute any documents (including new Secured Promissory Notes) reasonably required to effectuate and acknowledge each assignment of a Term Loan Commitment or Credit Extension to an assignee in accordance with Section 12.1, (ii) make Borrower’s management available to meet with Collateral Agent and prospective participants and assignees of Term Loan Commitments or Loans, or Credit Extensions (which meetings shall be conducted no more often than twice every twelve months unless an Event of Default has occurred and is continuing), and (iii) assist Collateral Agent or the Lenders in the preparation of information relating to the financial affairs of Borrower as any prospective participant or assignee of a Term Loan Commitment or Credit Extensions reasonably may request. Subject to the provisions of Section 12.9, Borrower authorizes each Lender to disclose to any prospective participant or assignee of a Term Loan Commitment, any and all information in such Lender’s possession concerning Borrower and its financial affairs which has been delivered to such Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender’s credit evaluation of Borrower prior to entering into this Agreement.”

 

8

 

 

2.21     Section 13.1 (Definitions) . The following terms and their respective definitions hereby are added or amended and restated in their entirety, as applicable, to Section 13.1 of the Loan Agreement as follows:

 

Amortization Date ” is, (i) with respect to the Term A Loans, (A) April 1, 2020, if the Term B Loans are funded prior to the end of the Second Draw Period, or (B) October 1, 2019, if the Term B Loans are not funded prior to the end of the Second Draw Period, (ii) with respect to the Term B Loans, April 1, 2020, and (iii) with respect to the Term C Loans, (A) April 1, 2020, if the Term B Loans are funded prior to the end of the Second Draw Period, or (B) if the Term B Loans are not funded prior to the end of the Second Draw Period, the first (1st) Payment Date following the Funding Date of the Term C Loans.

 

Basic Rate ” is with respect to a Term Loan, the floating per annum rate of interest (based on a year of three hundred sixty (360) days) equal to the greater of (i) eight and sixty-five hundredths of one percent (8.65%) and (ii) the sum of (A) the “prime rate” reported in the Wall Street Journal on the date occurring on the last Business Day of the month that immediately precedes the month in which the interest will accrue, plus (B) four and fifteen hundredths of one percent (4.15%). Notwithstanding the foregoing, the Basic Rate for the Term A Loans for the period from the Effective Date through and including February 28, 2018 shall be eight and sixty-five hundredths of one percent (8.65%).

 

Credit Extension ” is any Term Loan, or any other extension of credit by Collateral Agent or Lenders for Borrower’s benefit.

 

Maturity Date ” is September 1, 2022.

 

Original Loans ” is defined in Section 2.2(a)(i) hereof.

 

Original Revolving Loans ” is defined in Section 2.2(a)(i) hereof.

 

Original Term Loans ” is defined in Section 2.2(a)(i) hereof.

 

Oxford Term A Loan ” is defined in Section 2.2(a)(ii)(2) hereof.

 

Payment Date ” is the first (1st) calendar day of each calendar month, commencing on March 1, 2018 for the Term A Loans and April 1, 2018 for the Term B Loans.

 

Required Lenders ” means (i) for so long as all of the Persons that are Lenders on the Effective Date (each an “ Original Lender ”) have not assigned or transferred any of their interests in their Term Loans, Lenders holding one hundred percent (100%) of the aggregate outstanding principal balance of the Term Loans, or (ii) at any time from and after any Original Lender has assigned or transferred any interest in its Term Loans, Lenders holding at least sixty six percent (66%) of the aggregate outstanding principal balance of the Term Loans and, in respect of this clause (ii), (A) each Original Lender that has not assigned or transferred any portion of its Term Loans, (B) each assignee or transferee of an Original Lender’s interest in the Term Loans, but only to the extent that such assignee or transferee is an Affiliate or Approved Fund of such Original Lender, and (C) any Person providing financing to any Person described in clauses (A) and (B) above; provided, however, that this clause (C) shall only apply upon the occurrence of a default, event of default or similar occurrence with respect to such financing

 

Second Amendment Effective Date ” means February 16, 2018.

 

9

 

 

Second Amendment Final Payment ” is defined in Section 2.6(c)(ii) hereof.

 

Second Draw Period ” is the period (a) commencing on the date of the occurrence of the Second Tranche Milestone and (b) ending on the earlier of (i) December 31, 2018, (ii) the date that is sixty (60) days after the occurrence of the Second Tranche Milestone and (iii) the occurrence of an Event of Default; provided, however, that the Second Draw Period shall not commence if on the date of the occurrence of the Second Tranche Milestone an Event of Default has occurred and is continuing.

 

Second Tranche Milestone ” is the Lenders receipt, at any time after the Second Amendment Effective Date, of evidence satisfactory to the Lenders that Borrower has achieved trailing six (6) month product revenues of at least Twenty Million Dollars ($20,000,000.00) for the six (6) month period most recently ended.

 

SVB Term A Loan ” is defined in Section 2.2(a)(ii)(1) hereof.

 

Termination Fee ” is defined in Section 2.6(i) hereof.

 

Third Draw Period ” is the period (a) commencing on the date of the occurrence of the Third Tranche Milestone and (b) ending on the earlier of (i) March 31, 2019, (ii) the date that is sixty (60) days after the occurrence of the Third Tranche Milestone and (iii) the occurrence of an Event of Default; provided, however, that the Third Draw Period shall not commence if on the date of the occurrence of the Third Tranche Milestone an Event of Default has occurred and is continuing.

 

Third Tranche Milestone ” is the Lenders receipt, at any time after the Second Amendment Effective Date, of evidence satisfactory to the Lenders that Borrower has achieved trailing six (6) month product revenues of at least Twenty-Five Million Dollars ($25,000,000.00) for the six (6) month period most recently ended.

 

2.22     Section 13.1 (Definitions) . The following terms and their respective definitions hereby are deleted in their entirety from Section 13.1 of the Loan Agreement:

 

“Availability Amount”, “Borrowing Base”, “Borrowing Base Certificate”, “Revolving Advance” or “Revolving Advances”, “Revolving Line”, “Revolving Line Commitment”, “Revolving Line Commitment Percentage”, “Revolving Line Maturity Date”, “Transaction Report”

 

2.23       Schedule 1.1 of the Loan Agreement hereby is replaced in its entirety with Schedule 1.1 attached hereto.

 

2.24       Exhibit B-1 of the Loan Agreement hereby is replaced in its entirety with Exhibit B-1 attached hereto.

 

2.25       Exhibit C of the Loan Agreement hereby is replaced in its entirety with Exhibit C attached hereto.

 

2.26       Exhibit D of the Loan Agreement hereby is replaced in its entirety with Exhibit D attached hereto.

 

2.27       Exhibit E of the Loan Agreement hereby is replaced in its entirety with Exhibit E attached hereto.

 

2.28      The original Secured Promissory Note s dated as of March 18, 2016 and September 28, 2017 issued by Borrower in favor of SVB hereby are cancelled, null and void and of no further force and effect. The original Secured Promissory Notes in respect of the Original Term Loans by Oxford dated as of March 18, 2016 and September 28, 2017 and issued by Borrower in favor of Oxford hereby are amended and restated in the form attached as Exhibit E to the Loan Agreement, as amended by this Amendment, and such original Secured Promissory Notes that have been amended and restated are hereby cancelled, null and void and of no further force and effect. The original Secured Promissory Note in respect of the Original Revolving Loans by Oxford dated as of March 18, 2016 and issued by Borrower in favor of Oxford hereby is cancelled, null and void and of no further force and effect. Collateral Agent hereby acknowledges and agrees on behalf of the Lenders that no Prepayment Fee shall be due and payable by Borrower in connection with this Amendment and the transactions contemplated hereby, including, without limitation, the refinancing of the Original Loans.

 

10

 

 

3.     Limitation of Amendment.

 

3.1      T he amendments set forth in Section 2 above, are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Collateral Agent or any Lender may now have or may have in the future under or in connection with any Loan Document.

 

3.2      This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.

 

4.     Representations and Warranties. To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:

 

4.1      Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;

 

4.2      Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;

 

4.3      The organizational documents of Borrower delivered to Collateral Agent and Lenders on the Effective Date, or subsequent thereto, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;

 

4.4      The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;

 

4.5      The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;

 

4.6      The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower; and

 

4.7      This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.

 

11

 

 

5.     Counterparts. This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.

 

6.     Effectiveness. This Amendment shall be deemed effective upon the due execution and delivery to Collateral Agent and Lenders of the following:

 

(a)     this Amendment by each party hereto;

 

(b)     the due execution and delivery to Collateral Agent of the Corporate Borrowing Certificate s attached hereto;

 

(c)     the Disbursement Letter attached hereto;

 

(d)     Amended and Restated Secured Promissory Notes in favor of Oxford and each attached hereto;

 

(e)     a Secured Promissory Note in favor of SVB and attached hereto;

 

(f)     a Loan Payment/Advance Request form;

 

(g)     Borrower ’s payment of any outstanding Obligations in respect of the Original Revolving Loans; and

 

(h)     Borrower ’s payment of the Second Amendment Final Payment.

 

12

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above.  

 

 

COLLATERAL AGENT AND LENDER :

 

OXFORD FINANCE LLC 

 

 

By: /s/ Colette H. Featherly

Name:  Colette H. Featherly

Title:    Senior Vice President

 
   

 

LENDER:

 

SILICON VALLEY BANK

 

 

By: /s/ Kevin Fleischman

Name:  Kevin Fleischman

Title:    Director

 
   
   

BORROWER :

 

NUVECTRA CORPORATION

 

 

By: /s/ Walter Berger

Name:  Walter Berger

Title:    Chief Operating Officer and Chief Financial Officer

ALGOSTIM, LLC

 

 

By: /s/ Walter Berger

Name:  Walter Berger

Title:    Vice President and Treasurer

   

NEURONEXUS TECHNOLOGIES , INC.

 

 

By: /s/ Walter Berger

Name:  Walter Berger

Title:    Vice President and Treasurer

PELVISTIM LLC

 

 

By: /s/ Walter Berger

Name:  Walter Berger

Title:    Vice President and Treasurer

 

 

 

[Signature Page to Second Amendment to Loan and Security Agreement]

 

 

 

SCHEDULE 1.1

Lenders and Commitments

 

Term A Loans

Lender

Term A Loan Commitment

Term A Loan Commitment

Percentage

OXFORD FINANCE LLC

$ 13,750,000.00

50.00%

SILICON VALLEY BANK

$ 13,750,000.00

50.00%

TOTAL

$ 27 , 5 00,000.00

100.00%

 

Term B Loans

Lender

Term B Loan Commitment

Term B Loan Commitment

Percentage

OXFORD FINANCE LLC

$6,250,000.00

50.00%

SILICON VALLEY BANK

$6,250,000.00

50.00%

TOTAL

$12,500,000.00

100.00%

 

Term C Loans

Lender

Term C Loan Commitment

Term C Loan Commitment

Percentage

OXFORD FINANCE LLC

$2 ,500,000.00

50.00%

SILICON VALLEY BANK

$ 2,500,000.00

50.00%

TOTAL

$ 5 ,0 00,000.00

100.00%

 

Aggregate (all Term Loans)

Lender

Term Loan Commitment

Term Loan Commitment

Percentage

OXFORD FINANCE LLC

$22,5 00,000.00

50.00%

SILICON VALLEY BANK

$2 2,500,000.00

50.00%

TOTAL

$4 5 ,000,000.00

100.00%

 

 

 

 

EXHIBIT C

Compliance Certificate

 

TO:

OXFORD FINANCE LLC, as Collateral Agent and Lender
SILICON VALLEY BANK, as Lender

 

FROM:

NUVECTRA CORPORATION, ALGOSTIM, LLC, PELVISTIM LLC and NEURONEXUS TECHNOLOGIES, INC.

 

The undersigned authorized officer (“ Officer ”) of NUVECTRA CORPORATION, ALGOSTIM, LLC, PELVISTIM LLC and NEURONEXUS TECHNOLGIES, INC. (individually and collectively, jointly and severally, “ Borrower ”), hereby certifies that in accordance with the terms and conditions of the Loan and Security Agreement by and among Borrower, Collateral Agent, and the Lenders from time to time party thereto (the “ Loan Agreement ;” capitalized terms used but not otherwise defined herein shall have the meanings given them in the Loan Agreement),

 

a)     Borrower is in complete compliance for the period ending      with all required covenants except as noted below;

 

b)     There are no Events of Default, except as noted below;

 

c)     Except as noted below, all representations and warranties of Borrower stated in the Loan Documents are true and correct in all material respects on this date and for the period described in (a), above; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date.

 

d)     Borrower, and each of Borrower ’s Subsidiaries, has timely filed all required tax returns and reports, Borrower, and each of Borrower’s Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower, or Subsidiary, except as otherwise permitted pursuant to the terms of Section 5.8 of the Loan Agreement;

 

e)     No Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Collateral Agent and the Lenders.

 

Attached are the required documents, if any, supporting our certification(s). The Officer, on behalf of Borrower, further certifies that the attached financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and except, in the case of unaudited financial statements, for the absence of footnotes and subject to year-end audit adjustments as to the interim financial statements.

 

Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or N/A under “Complies” column.

 

 

Reporting Covenant

 

Requirement

 

Actual

Complies

             

1)

Financial statements

 

Quarterly within 5 days of filing with SECA

   

Yes

No

N/A

                 

2)

Annual (CPA Audited) statements

 

Within earlier of 180 days after FYE or 5 days of filing with SEC

   

Yes

No

N/A

 

 

 

 

  Reporting Covenant   Requirement   Actual Complies
                 

3)

Annual Financial Projections/Budget (prepared on a monthly basis)

 

Annually (within earlier of 30 days of FYE or 7 Business Days of approval by Board), and when revised

   

Yes

No

N/A

                 

4 )

8-K, 10-K and 10-Q Filings

 

If applicable, within 5 days of filing

   

Yes

No

N/A

                 

5 )

Compliance Certificate

 

Within 5 days of filing quarterly/annual financial statements with SEC

   

Yes

No

N/A

                 

6 )

IP Report

 

When required

   

Yes

No

N/A

                 

7 )

Total amount of Borrower ’s cash and cash equivalents at the last day of the measurement period

     

$_________

Yes

No

N/A

                 

8 )

Total amount of Borrower ’s Subsidiaries’ cash and cash equivalents at the last day of the measurement period

     

$_________

Yes

No

N/A

 

Deposit and Securities Accounts
( Please list all accounts; attach separate sheet if additional space needed )

 

 

Institution Name

Account Number

New Account?

Account Control Agreement in place?

         

1)

   

Yes

No

Yes

No

             

2)

           
             

3)

           
             

4)

           

 

Financial Covenants

 

 

Covenant

Requirement

Actual

Compliance

         

1)

Minimum Revenues (quarterly )

See Section 6.10

$

Yes

No

 

Other Matters

 

1)

Have there been any changes in management since the last Compliance Certificate?

Yes

No

       

2)

Have there been any transfers/sales/disposals/retirement of Collateral or IP prohibited by the Loan Agreement?

Yes

No

       

3)

Have there been any new or pending claims or causes of action against Borrower that involve more than Two Hundred Fifty Thousand Dollars ($250,000.00)?

Yes

No

 

 

 

 

4)

Subsidiary and to the Operating Documents of Borrower or any of its Subsidiaries? If yes, provide copies of any such amendments or changes with this Compliance Certificate.

Yes

No

 

Exceptions

 

Please explain any exceptions with respect to the certification above: (If no exceptions exist, state “No exceptions.” Attach separate sheet if additional space needed.)

 

NUVECTRA CORPORATION

ALGOSTIM, LLC PELVISTIM LLC

NEURONEXUS TECHNOLOGIES, INC.

 

 

By: __________________________________

Name: ________________________________

Title: _________________________________

 

Date:

   
   

LENDER USE ONLY

       
   

Received by:  __________________

Date: _______

       
   

Verified by: ____________________

Date: _______

       
   

Compliance Status  :

Yes

No

 

 

 

 

CORPORATE BORROWING CERTIFICATE

 

BORROWER: NUVECTRA CORPORATION DATE: February 16, 2018
LENDERS OXFORD FINANCE LLC, as Collateral Agent and Lender  
  SILICON VALLEY BANK , as Lender  

 

I hereby certify as follows, as of the date set forth above:

 

1.     I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below.

 

2.     Borrower ’s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State of Delaware.

 

3.     Attached hereto as Exhibit A and Exhibit B , respectively, are true, correct and complete copies of (i) Borrower’s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower’s Bylaws. Neither such Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.

 

4.     The following resolutions were duly and validly adopted by Borrower ’s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Collateral Agent and Lenders may rely on them until Collateral Agent and each Lender receives written notice of revocation from Borrower.

 

[Balance of Page Intentionally Left Blank]

 

 

 

 

RESOLVED , that any one of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:

 

 

Name

 

Title

 

Signature

 

Authorized to Add or Remove Signatories

           

             
           

             
           

             
           

 

Resolved Further , that any one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.

 

Resolved Further , that such individuals may, on behalf of Borrower:

 

Borrow Money . Borrow money from Lenders.

Execute Loan Documents . Execute any loan documents Collateral Agent or any Lender requires.

Grant Security . Grant Collateral Agent and Lenders a security interest in any of Borrower’s assets.

Negotiate Items . Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.

Further Acts . Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to effectuate such resolutions.

 

Resolved Further , that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.

 

5.          T he persons listed above are Borrower’s officers or employees with their titles and signatures shown next to their names.

 

  By:

 

  Name:

 

  Title:

 

 

*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.

 

I, the __________________________ of B orrower, hereby certify as to paragraphs 1 through 5 above, as                                

[print title]

of the date set forth above.

 

  By:

 

  Name:

 

  Title:

 

 

 

[Signature Page to Corporate Borrowing Certificate – Nuvectra Corporation]

 

 

 

CORPORATE BORROWING CERTIFICATE

 

BORROWER: NEURONEXUS TECHNOLOGIES, INC. DATE: February 16, 2018
LENDERS OXFORD FINANCE LLC, as Collateral Agent and Lender  
  SILICON VALLEY BANK, as Lender  

 

I hereby certify as follows, as of the date set forth above:

 

1.     I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below.

 

2.     Borrower ’s exact legal name is set forth above. Borrower is a corporation existing under the laws of the State of Michigan.

 

3.     Attached hereto as Exhibit A and Exhibit B , respectively, are true, correct and complete copies of (i) Borrower’s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower’s Bylaws. Neither such Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.

 

4.     The following resolutions were duly and validly adopted by Borrower ’s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action). Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Collateral Agent and Lenders may rely on them until Collateral Agent and each Lender receives written notice of revocation from Borrower.

 

[Balance of Page Intentionally Left Blank]

 

 

 

 

RESOLVED , that any one of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:

 

 

Name

 

Title

 

Signature

 

Authorized to Add or Remove Signatories

           

             
           

             
           

             
           

 

Resolved Further , that any one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.

 

Resolved Further , that such individuals may, on behalf of Borrower:

 

Borrow Money . Borrow money from Lenders.

Execute Loan Documents . Execute any loan documents Collateral Agent or any Lender requires.

Grant Security . Grant Collateral Agent and Lenders a security interest in any of Borrower’s assets.

Negotiate Items . Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.

Further Acts . Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to effectuate such resolutions.

 

Resolved Further , that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.

 

5.          T he persons listed above are Borrower’s officers or employees with their titles and signatures shown next to their names.

 

  By:

 

  Name:

 

  Title:

 

 

*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.

 

I, the __________________________ of B orrower, hereby certify as to paragraphs 1 through 5 above, as                               

[print title]

of the date set forth above.

 

  By:

 

  Name:

 

  Title:

 

 

 

[Signature Page to Corporate Borrowing Certificate – NeuroNexus Technologies, Inc.]

 

 

 

LIMITED LIABILITY COMPANY BORROWING CERTIFICATE

 

BORROWER: PELVISTIM LLC DATE: February 16, 2018
LENDERS OXFORD FINANCE LLC, as Collateral Agent and Lender  
  SILICON VALLEY BANK, as Lender  

 

I hereby certify as follows, as of the date set forth above:

 

1.     I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below.

 

2.     Borrower ’s exact legal name is set forth above. Borrower is a limited liability existing under the laws of the State of Delaware.

 

3.     Attached hereto as Exhibit A and Exhibit B , respectively, are true, correct and complete copies of (i) Borrower’s Certificate of Formation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower’s operating agreement. Neither such Certificate of Formation nor such operating agreement have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Formation and such operating agreement remain in full force and effect as of the date hereof.

 

4.     The following resolutions were duly and validly adopted by Borrower ’s sole member and Board of Managers. Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Collateral Agent and Lenders may rely on them until Collateral Agent and each Lender receives written notice of revocation from Borrower.

 

[Balance of Page Intentionally Left Blank]

 

 

 

 

 

RESOLVED , that any one of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:

 

 

Name

 

Title

 

Signature

 

Authorized to Add or Remove Signatories

           

             
           

             
           

             
           

 

Resolved Further , that any one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.

 

Resolved Further , that such individuals may, on behalf of Borrower:

 

Borrow Money . Borrow money from Lenders.

Execute Loan Documents . Execute any loan documents Collateral Agent or any Lender requires.

Grant Security . Grant Collateral Agent and Lenders a security interest in any of Borrower’s assets.

Negotiate Items . Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.

Further Acts . Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to effectuate such resolutions.

 

Resolved Further , that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.

 

5.     T he persons listed above are Borrower’s officers or employees with their titles and signatures shown next to their names.

 

  By:

 

  Name:

 

  Title:

 

 

*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.

 

I, the __________________________ of B orrower, hereby certify as to paragraphs 1 through 5 above, as                               
               [print title]

of the date set forth above.

 

  By:

 

  Name:

 

  Title:

 

 

 

[Signature Page to Limited Liability Company Borrowing Certificate – PelviStim LLC]

 

 

 

LIMITED LIABILITY COMPANY BORROWING CERTIFICATE

 

BORROWER: ALGOSTIM, LLC DATE: February 16, 2018
LENDERS OXFORD FINANCE LLC, as Collateral Agent and Lender  
  SILICON VALLEY BANK, as Lender  

 

I hereby certify as follows, as of the date set forth above:

 

1.     I am the Secretary, Assistant Secretary or other officer of Borrower. My title is as set forth below.

 

2.     Borrower ’s exact legal name is set forth above. Borrower is a limited liability existing under the laws of the State of Delaware.

 

3.     Attached hereto as Exhibit A and Exhibit B , respectively, are true, correct and complete copies of (i) Borrower’s Certificate of Formation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower’s operating agreement. Neither such Certificate of Formation nor such operating agreement have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Formation and such operating agreement remain in full force and effect as of the date hereof.

 

4.     The following resolutions were duly and validly adopted by Borrower ’s sole member and Board of Managers. Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and Collateral Agent and Lenders may rely on them until Collateral Agent and each Lender receives written notice of revocation from Borrower.

 

[Balance of Page Intentionally Left Blank]

 

 

 

 

 

RESOLVED , that any one of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower:

 

 

Name

 

Title

 

Signature

 

Authorized to Add or Remove Signatories

           

             
           

             
           

             
           

 

Resolved Further , that any one of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.

 

Resolved Further , that such individuals may, on behalf of Borrower:

 

Borrow Money . Borrow money from Lenders.

Execute Loan Documents . Execute any loan documents Collateral Agent or any Lender requires.

Grant Security . Grant Collateral Agent and Lenders a security interest in any of Borrower’s assets.

Negotiate Items . Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.

Further Acts . Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower’s right to a jury trial) they believe to be necessary to effectuate such resolutions.

 

Resolved Further , that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.

 

5.     T he persons listed above are Borrower’s officers or employees with their titles and signatures shown next to their names.

 

  By:

 

  Name:

 

  Title:

 

 

*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.

 

I, the __________________________ of B orrower, hereby certify as to paragraphs 1 through 5 above, as                               
               [print title]

of the date set forth above.

 

  By:

 

  Name:

 

  Title:

 

 

 

[Signature Page to Limited Liability Borrowing Certificate – AlgoStim, LLC]

Exhibit 99.1

 

Company Contacts:

Investor Contacts:

Nuvectra Corporation The Ruth Group
   
Walter Berger, COO & CFO Tram Bui / Brian Johnston
( 214) 474 - 3102 (646) 536-7035 / 7028
wberger@nuvectramed.com investors@nuvectramed.com

 

Nuvectra Secures $45 Million Second Amendment to

Existing Loan and Security Agreement

 

Agreement Provides Company with Increased Financial Flexibility and Extend ed Amortization Period

 

Plano, Texas, February 20 , 2018 – Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has reached an agreement with Silicon Valley Bank and Oxford Finance, the lenders of its existing credit facility, to secure a second amendment to the Company’s loan and security agreement for $45.0 million.

 

On February 16, 2018, the Company amended its loan and security agreement with Silicon Valley Bank and Oxford Finance to provide the Company with a $45.0 million term loan available in 3 tranche payments, from which the first tranche of $27.5 million was funded to repay the existing term loan in full, at the closing of the agreement.

 

In addition, on February 16, 2018 the Company drew down the second tranche commitment for $12.5 million following the achievement of the $20.0 million trailing six month product revenue milestone as of January 31, 2018. The third tranche commitment allows the Company to draw down another $5.0 million commencing on the date of achieving trailing six month product revenue of $25.0 million (the “Third Tranche Milestone”) and ending on the earlier of March 31, 2019 or sixty (60) days following the Third Tranche Milestone. The third tranche commitment replaces the existing $5.0 million revolving line commitment.

 

The amended agreement also extends the amortization period of the loan with principal payments scheduled to begin April 2020 based on the drawn second tranche.

 

Walter Berger, Chief Operating Officer & Chief Financial Officer , commented, “We are pleased to announce the amended loan and security agreement that provides the Company with greater financial flexibility and an extended amortization period. This agreement, together with our recently completed follow-on common stock offering that raised approximately $26.0 million in gross proceeds, will allow the Company to continue to drive our U.S. commercial expansion of the Algovita ® system and plan our entry into the SNM market. We appreciate our continued relationship with Silicon Valley Bank and Oxford Finance and their continued confidence in our ability to execute on our near and long term corporate initiatives.”

 

 

 

About Nuvectra Corporation

 

Nuvectra TM is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita ® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.

 

 

-1-

 

 

About Silicon Valley Bank

 

For 3 5 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators. Learn more at svb.com.

 

 

 

About Oxford Finance LLC

 

Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $4 billion in loans, with lines of credit ranging from $5 million to $100 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in San Diego, California; Palo Alto, California; and the greater Boston and New York City areas. For more information, visit oxfordfinance.com.  

 

 

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains "forward-looking statements," including statements we make regarding the outlook for  Nuvectra as an independent publicly-traded company. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and therefore they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and may be outside of our control. Our actual performance may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us is based only on information currently available to us and speaks only as of the date on which it is made.  Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include: (i) our ability to successfully commercialize Algovita and to develop, complete and commercialize enhancements or improvements to Algovita; (ii) our ability to successfully compete with our current SCS competitors and the ability of our U.S. sales representatives to successfully establish market share and acceptance of Algovita, (iii) the uncertainty of obtaining regulatory approvals in the United States and Europe for our Virtis SNM system, (iv) our ability to successfully launch and commercialize the Virtis SNM system if it receives regulatory approval (v) our ability to demonstrate the features, perceived benefits and capabilities of Algovita to physicians and patients in competition with similar products already well established and sold in the SCS market; (vi) our ability to anticipate and satisfy customer needs and preferences and to develop, introduce and commercialize new products or advancements and improvements to Algovita in order to successfully meet our customers’ expectations; (vii) the outcome of our development plans for our neurostimulation technology platform, including our ability to identify additional indications or conditions for which we may develop neurostimulation medical devices or therapies and seek regulatory approval thereof; (viii) our ability to identify business development and growth opportunities and to successfully execute on our strategy, including our ability to seek and develop strategic partnerships with third parties to, among other things, fund clinical and development costs for new product offerings; (ix) the performance by our development partners, including Aleva Neurotherapeutics, S.A., of their obligations under their agreements with us; (x) the scope of protection for our intellectual property rights covering Algovita and other products using our neurostimulation technology platform, along with any product enhancements or improvements; (xi) our ability to successfully build, attract and maintain an effective commercial infrastructure and qualified sales force in the United States; (xii) our compliance with all regulatory and legal requirements regarding implantable medical devices and interactions with healthcare professionals; (xiii) any supplier shortages related to Algovita or its components and any manufacturing disruptions which may impact our inventory supply as we expand our business, (xiv) any product recalls, or the receipt of any warning letters, mandatory corrections or fines from any governmental or regulatory agency; (xv) our ability to satisfy the conditions and covenants, including trailing six month revenue milestones, of our Credit Facility; and (xvi) our ability to raise capital through means other than or in addition to the Credit Facility should it become necessary to do so, through a public offering of our common stock, private equity or debt financings, strategic partnerships, or other sources. Please see the section entitled “Risk Factors” in Nuvectra’s Annual Report on Form 10-K and in our other quarterly and periodic filings for a description of these and other risks and uncertainties.  We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

 

-2-